Key Takeaways
- Shares of NVS declined approximately 2% during pre-market trading following disappointing first-quarter financial results
- Revenue totaled $13.11B, falling short of Wall Street’s $13.40B projection and representing a 1% year-over-year decline
- Sales of Entresto plummeted 42% to $1.31B following U.S. patent expiration and the introduction of generic alternatives
- Core earnings per share decreased to $1.99 from $2.28 in the prior-year period; core operating profit contracted 12% to $4.9B
- Chief Executive Vas Narasimhan cautioned that the U.S. “most favored nation” pricing framework could restrict patient access to innovative therapies in Europe and Japan over the next 18 months
The pharmaceutical giant Novartis kicked off 2026 on a challenging note, delivering first-quarter financial performance that fell short of Wall Street projections on both the top and bottom lines as generic competition proved more severe than anticipated.
Revenue registered at $13.11 billion, missing analyst estimates of $13.40 billion. Core operating profit contracted 12% to reach $4.9 billion, which also came in below the approximately $5.1 billion consensus figure compiled by Visible Alpha.
The primary driver behind the disappointing results was Entresto, the company’s flagship cardiovascular medication. Revenue from this treatment plunged 42% to $1.31 billion following the expiration of U.S. patent protection and subsequent generic market entry. Wall Street had anticipated sales of $1.37 billion.
Entresto represented 14% of overall revenue in the previous year, making this patent expiration one of the most significant revenue headwinds in the company’s recent operating history. Chief Executive Vas Narasimhan has characterized it as the most substantial patent cliff Novartis has encountered in twenty years.
The challenges extend beyond Entresto alone. Medications including Promacta for blood disorders and Tasigna for leukemia treatment are similarly confronting generic competition, compounding the difficulties in achieving revenue growth.
Core earnings per share slipped to $1.99, down from $2.28 during the comparable quarter last year. Operating income decreased 9% while net income fell 13%, reflecting both the revenue shortfall and elevated research and development expenditures.
Chief Financial Officer Mukul Mehta informed reporters that the performance aligned with the company’s internal projections. He indicated the organization anticipates “growth to return back to our P&L in the second half of this year.”
Novartis maintained its full-year outlook, citing a robust pipeline of experimental drugs and continued product launches. Management projects approximately $4 billion in revenue erosion this year attributable to generic competition affecting Entresto, Promacta, and Tasigna.
Chief Executive Highlights Drug Pricing Policy Concerns
Beyond the quarterly financial results, CEO Narasimhan utilized the earnings announcement to express apprehension regarding U.S. pharmaceutical pricing regulations, particularly the “most favored nation” framework.
The MFN mechanism links U.S. medication prices to those paid in other developed nations. Narasimhan cautioned that the ramifications would extend internationally, stating “the reality of MFN is going to set in in the next 18 months.”
He indicated that Novartis is encouraging European and Japanese authorities to reconsider their pricing and reimbursement approaches for innovative medicines. Absent such modifications, he cautioned that “novel medicines might see delayed entry” and patient access could be compromised.
Currently, the immediate financial impact on Novartis remains modest. MFN presently affects approximately 5% to 10% of Medicaid-related revenue. However, Narasimhan views the policy as permanent. “I don’t see it disappearing in the U.S.,” he remarked.
His statements mirror concerns voiced by industry peers. Pharmaceutical companies including Roche and AstraZeneca have similarly identified Europe’s pricing infrastructure as an escalating threat to future medication accessibility.
Analyst Community Maintains Constructive Outlook
Notwithstanding the quarterly disappointment, the investment community has not abandoned its support for the shares. Novartis maintains a Moderate Buy consensus rating derived from six analyst assessments.
The consensus price target stands at $169.86, suggesting approximately 17% appreciation potential from present trading levels.
Entresto will confront additional patent expirations in European markets beginning in November, which will introduce further revenue pressure during the latter portion of the year.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
